Compare BIO-TECHNE Corp (TECH) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Wynn Resorts, Limited — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Wynn Resorts, Limited trades at $105 (market cap $10.55B). The key difference: BIO-TECHNE Corp and Wynn Resorts, Limited are close in size by market cap, and Wynn Resorts, Limited pays the higher dividend (0.98%). Which is the better fit depends on your goals.
| TECH | WYNN | |
|---|---|---|
Market Cap | $11.24B | $10.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $72.29 | $133.34 |
52-Week Low | $43.31 | $94.37 |
Enterprise Value | $11.32B | $20.80B |
Dividend Yield | 0.44% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Wynn Resorts (WYNN) trades at $102.54, up 1.02% today, with a bullish technical signal from moving averages and support at $101. The company reported Q2 2026 earnings of $1.24 per share, beating estimates, driven by strong performance in Macau. Revenue trends show growth from $3.8B in 2022 to $7.4B projected for 2026, though net margins have fluctuated. Recent news highlights institutional buying and CapEx plans for new resorts.
The outlook is positive with a consensus price target of $133, implying 30% upside, supported by analyst bullishness (64% buy ratings). Risks include high debt levels ($10.5B long-term) and sensitivity to tourism cycles. Earnings consistency and Macau's recovery remain key catalysts for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
